Asset Details
Do you wish to reserve the book?
Modulating the developing gut microbiota with 2’-fucosyllactose and pooled human milk oligosaccharides
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Modulating the developing gut microbiota with 2’-fucosyllactose and pooled human milk oligosaccharides
Do you wish to request the book?
Modulating the developing gut microbiota with 2’-fucosyllactose and pooled human milk oligosaccharides
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Modulating the developing gut microbiota with 2’-fucosyllactose and pooled human milk oligosaccharides
2025
Overview
Background
Synthetic human milk oligosaccharides (HMOs) are used to supplement infant formula despite limited understanding of their impact on the post-weaned developing gut microbiota. Here, we assess the influence of 0.5 g/L 2-fucosyllactose (2’FL) and 4.0 g/L pooled HMOs (pHMOs) on the composition and activity of cultured fecal-derived microbial communities from seven healthy young children.
Results
Exposure to pHMOs induced significant shifts in both the microbial community composition and metabolic output, including an increased abundance of several genera, notably
Bacteroides
, and the production of health-associated metabolites. In contrast, 2’FL alone did not lead to substantial changes in the communities. A total of 330 bacterial isolates, spanning 157 species, were cultured from these communities and individually evaluated for their responses to HMOs. Over 100 non-
Bifidobacterium
species showed enhanced growth upon pHMOs treatment and a high degree of intraspecies variation in HMO metabolism was observed.
Conclusion
Our study provides valuable insight into the health-enhancing properties of HMOs while highlighting the need for future research into the efficacy of incorporating individual structures into infant formula, particularly when aiming to modulate the gut microbiota.
DLoTGpXbSBXfYGWsHwkdt7
Video Abstract
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Bacteria - growth & development
/ Bacteria - isolation & purification
/ Biomedical and Life Sciences
/ Female
/ Gastrointestinal Microbiome - drug effects
/ Humans
/ Infant
/ Male
/ Microbial Genetics and Genomics
/ Microbiota (Symbiotic organisms)
/ Oligosaccharides - pharmacology
/ Trisaccharides - pharmacology
/ Virology
